APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 1882, the FAIR Generics Act S. 27, the Preserve Access to Affordable Pharmaceuticals Act HR 3995, the Protecting Consumer Access to Generic Drugs Act S. 296, HR 2245, The Preserving Access to Life Savings Medications Act HR 4332, the Generic Drug Application Review Fairness Act HR 3998, Generic Drug and Biosimilar User Fee Act HR 2182, S. 1734, the Generating Antibiotic Incentives Now Act Amending Section 505(j) of the Food, Drug, and Cosmetic Act, concerning the ability of generic pharmaceutical manufacturers to file counterclaims seeking the correction of incorrect information submitted to FDA's Orange Book by patent owners or holders of New Drug Applications Supreme Court consideration of Novo Nordisk A/S and Novo Nordisk Inc. vs Caraco Pharmaceutical Laboratories Ltd. and Sun Pharmaceuticals Industries, Ltd. Prospective legislation establishing a generic drug user fee program Prospective legislation establishing a biosimilar user fee program Establishment of a federal track and trace system for pharmaceuticals The use of Risk Evaluation Mitigation Strategies (REMS) programs by brand drug companies to delay generic competition International Nonproprietary Names for Biosimilars
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Shermfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | Legislative Director, Congressman Frank Pallone |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.